Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

3(21%)

Results Posted

60%(3 trials)

Terminated

1(7%)

Phase Distribution

Ph early_phase_1

Ph not_applicable

29%

Ph phase_2

43%

Ph phase_1

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Early Phase 1First-in-human

1(7.7%)

Phase 1Safety & dosage

2(15.4%)

Phase 2Efficacy & side effects

6(46.2%)

N/ANon-phased studies

4(30.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(5)

Terminated(1)

Other(5)

Detailed Status

Completed5

unknown4

Recruiting3

Terminated1

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (7.7%)

Phase 12 (15.4%)

Phase 26 (46.2%)

N/A4 (30.8%)

Trials by Status

terminated17%

suspended17%

completed536%

unknown429%

recruiting321%

Recent Activity

3 active trials

Showing 5 of 14

recruitingphase_1

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

NCT05562791

recruitingphase_2

Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

NCT05527483

View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials

NCT05562791Phase 1

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

Recruiting

NCT06560905Phase 2

Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

Recruiting

NCT03453528Not Applicable

Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors

Completed

NCT06484361Phase 2

PET/MRI to Stage Prostate Cancer Patients

Recruiting

NCT05527483

Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

Completed

NCT06355843Not Applicable

Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.

Suspended

NCT03396874Phase 2

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

Completed

NCT04614363Phase 1

68 Ga-PSMA for High Risk Prostate Cancer

Completed

NCT05806853Phase 2

PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study

Completed

NCT05006326Not Applicable

Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma

Unknown

NCT03689582Phase 2

Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer

Terminated

NCT05170555Not Applicable

Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617

Unknown

NCT04801264Early Phase 1

Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617

Unknown

NCT02282137Phase 2

68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

Unknown

All 14 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 14